About 40% of individuals had scarring patterns on their heart muscle visible during imaging, which was associated with a greater risk of suffering a major cardiac event.

Stress cardiomyopathy—often referred to as broken heart syndrome—was up significantly in March and April 2020.

preCARDIA announced that its catheter-based system for acutely decompensated heart failure has received the FDA’s breakthrough device designation.

Tafamidis received FDA approval in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It has a list price of $225,000 per year.

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

The study's authors emphasized the importance of interventions such as patient communication and education. 

With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.